HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SBI-425

an inhibitor of tissue-nonspecific alkaline phosphatase; structure in first source

Also Known As:

5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niacinamide: 2223
        SBI-425: 7
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niacinamide: 2223
      - SBI-425: 7
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - SBI-425: 7
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - SBI-425: 7

Experts

1.	Millán, José Luis: 3 articles (01/2020 - 01/2017)
2.	Pinkerton, Anthony B: 3 articles (01/2020 - 01/2017)
3.	D'Haese, Patrick C: 2 articles (01/2020 - 01/2020)
4.	Opdebeeck, Britt: 2 articles (01/2020 - 01/2020)
5.	Verhulst, Anja: 2 articles (01/2020 - 01/2020)
6.	Balayssac, Stéphane: 1 article (06/2022)
7.	Bessueille, Laurence: 1 article (06/2022)
8.	Bouillot, Caroline: 1 article (06/2022)
9.	Briolay, Anne: 1 article (06/2022)
10.	Buchet, René: 1 article (06/2022)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/2017 - "In a placebo-controlled experiment under atherogenic conditions, pharmacological inhibition of TNAP in WHC-eTNAP mice by a specific inhibitor SBI-425 (30mgkg-1d-1, for 5 weeks) reduced coronary calcium (78838 vs.144622μm2) and lipids (30754 vs. 77317μm2); improved body weight (22.4 vs.18.8g) and ejection fraction (59 vs. 47%). "
2.	Atherosclerosis 01/01/2023 - "In this study, we sought to investigate the effect of the recently developed TNAP inhibitor SBI-425 on atherosclerosis plaque calcification and progression. "
3.	Vascular Calcification 01/01/2020 - "Administration of TNAP inhibitor SBI-425 significantly reduced the calcification in the aorta and peripheral arteries of a rat model of warfarin-induced vascular calcification. " 01/01/2020 - "Daily administration of the TNAP inhibitor SBI-425 (10 mg/kg/day) for 7 weeks significantly reduced vascular calcification as indicated by a significant decrease in calcium content in the aorta (vehicle 3.84 ± 0.64 mg calcium/g wet tissue vs TNAP inhibitor 0.70 ± 0.23 mg calcium/g wet tissue) and peripheral arteries and a distinct reduction in area % calcification on Von Kossa stained aortic sections as compared to vehicle. " 01/01/2020 - "To investigate the effect of the pharmacological TNAP inhibitor SBI-425 on vascular calcification and bone metabolism, a 0.30% warfarin rat model was used. "
4.	Sepsis (Septicemia) 12/11/2019 - "To elucidate the role of TNAP at the brain-immune axis, mice were subjected to experimental sepsis and received either vehicle or SBI-425 (25 mg/kg, IP) daily for 7 days. "
5.	Glucose Intolerance 01/01/2023 - "Interestingly, treating pregnant DBA/2J mice with 7.5 mg/kg/day of the ALPL inhibitor SBI-425 is associated with glucose intolerance in low vitamin B6-fed mice, implying that inhibition of ALPL activity is sufficient to modulate resilience to low vitamin B6-induced metabolic impairment."

Related Drugs and Biologics

1.	Calcium
2.	Lipids
3.	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)
4.	Warfarin (Coumadin)
5.	Vitamins
6.	Steroids
7.	Glucose (Dextrose)
8.	Fatty Acids (Saturated Fatty Acids)